MRD testing is a reliable endpoint for the assessment of deep responses in myeloma clinical trials

Brian Durie, MD, Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, discusses measurable residual disease (MRD) as an endpoint in myeloma clinical trials. The International Myeloma Foundation (IMF) gathered data from 20 clinical trials using MRD as an endpoint and concluded that the combination of MRD with complete responses (CR) was a reliable predictor of progression-free survival (PFS). This means MRD testing can be incorporated into upcoming trials as a reliable endpoint for the assessment of deep responses. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.